⚕ *Join Us for an Important COVID-19 Webinar*

The Clinical Impact of Tight vs Standard Glycemic Control on COVID-19 Hospitalized Patients

Diabetes and stress hyperglycemia are two of the most common co-morbidities of COVID-19. Two recent multi-center studies of 8,500 COVID-19 hospitalized patients have found that type 2 diabetes (T2D) and poor glycemic control are risk factors for COVID-19 disease progression and adverse outcome. This webinar will review clinical characteristics and mortality of COVID-19 patients with pre-existing T2D, and possible avenues to improving their disease outcomes. Clinical evidence supporting tight glycemic management of T2D during COVID will be presented.

The webinar will also describe the growing interest in the antioxidant properties of ascorbic acid as an adjunctive therapy for COVID-19. For these critically ill patients, severe anemia is also a common underlying condition. This webinar examines the risk of inaccurate glucose meter results due to interference from ascorbic acid and anemia. A glucose meter that measures and corrects for these interferences will also be described.

Learning Objectives

- Frequency of T2D among a multi-center cohort of 8,500 COVID-19 hospitalized patients
- Risk of T2D patients developing more severe cases of COVID-19, including ARDS, septic shock and MODS
- Outcome of T2D patients with well controlled glycemic variability versus those with poorly controlled glycemic variability
- Use of adjunctive therapies such as ascorbic acid with COVID-19 patients
- Evidence based risk of glucose meter error due to ascorbic acid and anemia interferences
- Risk mitigation for hospitals in protecting their COVID-19 patients from erroneous bedside glucose tests

Educational Credits

- This program offers 1 hour of P.A.C.E. continuing education credit.
- This program has been approved by the American Association of Critical-Care Nurses (AACN), for 1.00 CERPs, Synergy CERP Category A, File Number 23205. Approval refers to recognition of continuing education only and does not imply AACN approval or endorsement of the content of this educational activity, or the products mentioned.

Presenters:

Bruce Bode, MD, FACE
Atlanta Diabetes Associates,
Atlanta, Georgia;
Clinical Associate Professor,
Department of Medicine
Emory University

Jeffery A. DuBois, PhD,
HCLD/CC (ABB), FACP,
Vice President of Medical
and Scientific Affairs
Nova Biomedical

Three Webinar Times are Available:

Thursday, July 23rd, 1 PM Eastern Daylight Time
Thursday, Aug. 6th, 4 PM Eastern Daylight Time
Thursday, Aug. 20th, 1 PM Eastern Daylight Time

Register Now at:

novabiomedical.com/clinicalimpact/covid19

nova® *biomedical*
novabiomedical.com